Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Tomas Lafarga & Maria Hayes. (2017) Bioactive protein hydrolysates in the functional food ingredient industry: Overcoming current challenges. Food Reviews International 33:3, pages 217-246.
Read now
Read now
Yutaka Seino & Daisuke Yabe. (2014) Alogliptin for the treatment of Type 2 diabetes. Expert Review of Endocrinology & Metabolism 9:6, pages 547-559.
Read now
Read now
Antonio Ceriello, Liberata Sportiello, Concetta Rafaniello & Francesco Rossi. (2014) DPP-4 inhibitors: pharmacological differences and their clinical implications. Expert Opinion on Drug Safety 13:sup1, pages 57-68.
Read now
Read now
Yutaka Seino & Daisuke Yabe. (2014)
Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 15:6, pages 851-863.
Read now
Read now
Articles from other publishers (18)
Lily Park, Claudia Green, Sergey Arutyunyan, Gabriella Vasile, Christopher Buckley & Eduardo Weiss. (2022) Effects of canary seed on two patients with disseminated granuloma annulare. Dermatology Reports.
Crossref
Crossref
Yongting Zhao, Xiaofang Zhang, Haihai Liang & Lihong Wang. (2022) Antidiabetic agents: Do they hit the right targets?. Frigid Zone Medicine 2:4, pages 225-243.
Crossref
Crossref
Konstantin G. Gurevich, Yulia A. Sorokina, Alexander L. Urakov, Snezhana D. Sinyushkina, Maria I. Pryazhnikova, Alyona V. Gorinova, Lyubov V. Lovtsova & Olga V. Zanozina. (2022) Immunotropic effects of hypoglycemic agents on coronavirus infection: a view from the perspective of pharmacogenetics. Reviews on Clinical Pharmacology and Drug Therapy 20:3, pages 269-279.
Crossref
Crossref
Prawej Ansari, Samara T. Choudhury, Veronique Seidel, Akib Bin Rahman, Md. Abdul Aziz, Anika E. Richi, Ayesha Rahman, Umme H. Jafrin, J. M. A. Hannan & Yasser H. A. Abdel-Wahab. (2022) Therapeutic Potential of Quercetin in the Management of Type-2 Diabetes Mellitus. Life 12:8, pages 1146.
Crossref
Crossref
Marta Wolosowicz, Slawomir Prokopiuk & Tomasz W. Kaminski. (2022) Recent Advances in the Treatment of Insulin Resistance Targeting Molecular and Metabolic Pathways: Fighting a Losing Battle?. Medicina 58:4, pages 472.
Crossref
Crossref
Bruno Dutra Arbo, Lucia Emanueli Schimith, Michele Goulart dos Santos & Mariana Appel Hort. (2022) Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation. European Journal of Pharmacology 919, pages 174800.
Crossref
Crossref
Ana Maria Udrea, Gratiela Gradisteanu Pircalabioru, Anca Andreea Boboc, Catalina Mares, Andra Dinache, Maria Mernea & Speranta Avram. (2021) Advanced Bioinformatics Tools in the Pharmacokinetic Profiles of Natural and Synthetic Compounds with Anti-Diabetic Activity. Biomolecules 11:11, pages 1692.
Crossref
Crossref
Chin-Ying Ray, Victor Chien-Chia Wu, Chun-Li Wang, Hui-Tzu Tu, Yu-Tung Huang, Chang-Fu Kuo & Shang-Hung Chang. (2021) Hypoglycemia Associated With Drug–Drug Interactions in Patients With Type 2 Diabetes Mellitus Using Dipeptidylpeptidase-4 Inhibitors. Frontiers in Pharmacology 12.
Crossref
Crossref
Md Kamruzzaman, Michael Horowitz, Karen L. Jones & Chinmay S. Marathe. (2021) Gut-Based Strategies to Reduce Postprandial Glycaemia in Type 2 Diabetes. Frontiers in Endocrinology 12.
Crossref
Crossref
Mariusz Dąbrowski. (2021) Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors. International Journal of Molecular Sciences 22:4, pages 1680.
Crossref
Crossref
Sonia Rocha, Daniela Ribeiro, Eduarda Fernandes & Marisa Freitas. (2020) A Systematic Review on Anti-diabetic Properties of Chalcones. Current Medicinal Chemistry 27:14, pages 2257-2321.
Crossref
Crossref
L. V. Kondratyeva. (2019) Early combination therapy for type 2 diabetes. Time for new decisions. Medical Council:12, pages 115-121.
Crossref
Crossref
N. A. PetuninaA. L. Terekhova. (2019) Reliable choice in therapy of type 2 diabetes mellitus: focus on alogliptin. Medical Council:21, pages 138-145.
Crossref
Crossref
N. A. Petunina, E. V. Goncharova & S. A. Potapova. (2017) CARDIOVASCULAR SAFETY OF GLIPTINS. FOCUS ON ALOGLIPTIN. Medical Council:3, pages 32-37.
Crossref
Crossref
Carlo B. Giorda, Elisa Nada & Barbara Tartaglino. (2014) Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature. Endocrine 46:3, pages 406-419.
Crossref
Crossref
Sandeep Chakraborty, Adela Rendón-Ramírez, Bjarni Ásgeirsson, Mouparna Dutta, Anindya S. Ghosh, Masataka Oda, Ravindra Venkatramani, Basuthkar J. Rao, Abhaya M. Dandekar & Félix M. Goñi. (2015) The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins. F1000Research 2, pages 286.
Crossref
Crossref
Sandeep Chakraborty, Adela Rendón-Ramírez, Bjarni Ásgeirsson, Mouparna Dutta, Anindya S. Ghosh, Masataka Oda, Ravindra Venkatramani, Basuthkar J. Rao, Abhaya M. Dandekar & Félix M. Goñi. (2015) Dipeptidyl peptidase-IV inhibitors used in type-2 diabetes inhibit a phospholipase C: a case of promiscuous scaffolds in proteins. F1000Research 2, pages 286.
Crossref
Crossref
Sandeep Chakraborty, Adela Rendón-Ramírez, Bjarni Ásgeirsson, Mouparna Dutta, Anindya S. Ghosh, Masataka Oda, Ravindra Venkatramani, Basuthkar J. Rao, Abhaya M. Dandekar & Félix M. Goñi. (2013) Dipeptidyl peptidase-IV inhibitors used in type-2 diabetes inhibit a phospholipase C: a case of promiscuous scaffolds in proteins. F1000Research 2, pages 286.
Crossref
Crossref